Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors

HER2-targeted therapies are approved only for HER2-positive breast and gastric cancers. We assessed the safety/tolerability and activity of the novel HER2-targeted antibody–drug conjugate trastuzumab deruxtecan (T-DXd) in 60 patients with pretreated, HER2-expressing (IHC ≥ 1+), non-breast/non-gastri...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Discov
Autori principali: Tsurutani, Junji, Iwata, Hiroji, Krop, Ian, Jänne, Pasi A., Doi, Toshihiko, Takahashi, Shunji, Park, Haeseong, Redfern, Charles, Tamura, Kenji, Wise-Draper, Trisha M., Saito, Kaku, Sugihara, Masahiro, Singh, Jasmeet, Jikoh, Takahiro, Gallant, Gilles, Li, Bob T.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8292921/
https://ncbi.nlm.nih.gov/pubmed/32213540
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-19-1014
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi